Abstract Sodium–glucose cotransporter 2 (SGLT2) inhibitors reduce heart failure events by
direct action on the failing heart that is independent of changes in renal tubular function. In …

Iron deficiency (ID) is common in patients with cardiovascular disease. Up to 60% of patients
with coronary artery disease, and an even higher proportion of those with heart failure (HF) …

Background Ferric carboxymaltose therapy reduces symptoms and improves quality of life in
patients who have heart failure with a reduced ejection fraction and iron deficiency …

Heart failure with preserved ejection fraction (HFpEF) represents a highly heterogeneous
clinical syndrome affected in its development and progression by many comorbidities. The …

Aims For patients with heart failure (HF) and iron deficiency (ID), randomized trials suggest
that intravenous (IV) iron reduces hospitalizations for heart failure (HHF), but uncertainty …

Background: Iron deficiency is common in heart failure and associated with worse outcomes.
We examined the prevalence and consequences of iron deficiency in the DAPA-HF trial …

Background For patients with heart failure, reduced left ventricular ejection fraction and iron
deficiency, intravenous ferric carboxymaltose administration improves quality of life and …

Many patients with symptoms and signs of heart failure have a left ventricular ejection
fraction≥ 50%, termed heart failure with preserved ejection fraction (HFpEF). HFpEF is a …

Many patients with heart failure have an iron‐deficient state, which can limit erythropoiesis in
erythroid precursors and ATP production in cardiomyocytes. Yet, treatment with sodium …

In patients with heart failure, sodium-glucose cotransporter 2 (SGLT2) inhibitors have been
shown to decrease hepcidin and ferritin and increase transferrin receptor protein, changes …